Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver disease
A single subcutaneous dose of WVE-006 in the first two patients with homozygous “ZZ” AATD resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT; durable editing with M-AAT protein observed through 57 days
Wave expects to share multidose data from the RestorAATion-2 trial in 2025
Annual Research Day on October 30th will highlight WVE-006 proof-of-mechanism data and Wave’s new wholly owned GalNAc-RNA editing programs, in addition to an obesity program update with new preclinical data for WVE-007 (INHBE GalNAc-siRNA)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.